Our Q4 2013 Outlook Report highlighted several high-impact catalysts that resulted in large stock price changes. The results of all of our Q4 catalysts can be found on Page 4 of this report. BioMedTracker Likelihood of Approval (LOA) opinions successfully predicted 77% of catalyst outcomes in Q4 2013.

In this quarter's report, we cover catalysts from 25 drugs and 6 devices and have included a list of Large Impact catalysts in the drug, device/diagnostic, and natural resource areas through April 2014 from our sister product, CatalystTracker. In addition, each drug’s likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. Please note the current LOAs displayed on BioMedTracker are not based on these new probabilities; these new data will be integrated at a later time.

For the full report, please download the PDF version at the top of this page. Additionally, the catalyst calendars are provided in Excel by downloading the supplemental material above.

For our disclosures, please read the BioMedTracker Research Standards.